Minnesota House lawmakers voted Thursday to establish a regulated psilocybin therapy program for adults, marking the latest state move toward psychedelic medicine reform.
The measure passed 114-15 as a floor amendment to broader health policy legislation. The bipartisan support signals growing legislative acceptance of psychedelic-assisted therapy, following similar moves in Oregon and Colorado.
Under the approved language, adults 21 and older would gain access to psilocybin through a regulated therapeutic framework. The amendment now moves to the Senate as part of the larger health omnibus bill.
The Cannabis Industry Connection
The vote comes as cannabis businesses increasingly eye the psychedelic space. Several multi-state operators have launched psychedelic research divisions, anticipating regulatory pathways similar to medical cannabis programs.
Minnesota legalized adult-use cannabis in 2023, and the state's Office of Cannabis Management has become a model for other states. Industry observers expect any psilocybin framework would likely mirror cannabis regulatory structures—licensed facilities, track-and-trace systems, and strict therapeutic protocols.
The overwhelming House vote (88% approval) far exceeded typical cannabis legislation margins. Psychedelic therapy bills have gained traction partly by framing access as mental health treatment rather than recreational use, avoiding some political headwinds that cannabis reforms face.
What Happens Next
The Senate must now consider the amended health bill. Minnesota's legislative session typically runs through mid-May, giving lawmakers roughly six weeks to reconcile any differences between House and Senate versions.
If the Senate approves the psilocybin provisions, Minnesota would join Oregon and Colorado in creating legal frameworks for therapeutic psychedelic use. Oregon launched its program in 2023, while Colorado voters approved regulated access in 2022 with implementation ongoing.
The Minnesota Department of Health would likely oversee program development, similar to how the state structured its medical cannabis rollout before adult-use legalization. Industry stakeholders expect a 12-18 month implementation timeline if the bill becomes law.
Several other states—including California, Massachusetts, and Washington—are considering similar psychedelic therapy measures this year. The Minnesota vote could accelerate momentum in those legislatures, particularly given the strong bipartisan support.
This article is based on original reporting by www.marijuanamoment.net.
